Brain Tumor Small Molecule Inhibitor Development

Small molecule inhibitors are a class of biologically active small molecule compounds. They include various types of enzyme inhibitors, transcription factor inhibitors, metabolic pathway inhibitors, and proton pump inhibitors. Compared to most antibodies, small molecules can easily penetrate tissues. Therefore, they can target extracellular and intracellular targets to promote the anti-brain tumor process.

These substances also have potential complementary or synergistic effects with existing immunotherapies. Compared to therapeutic antibodies, small molecule drugs are more permeable to the tumor microenvironment. The ability to cross physiological barriers such as the blood-brain barrier offers new options for the treatment of brain tumors and brain metastases. By tuning pharmacokinetic and pharmacodynamic parameters, small molecule drugs may provide optimal bioavailability and avoid some of the side effects associated with long-acting antibody therapy.

We offer small-molecule inhibitor development services for brain tumors

Alfa Cytology is continuously developing new brain tumor-related genes, such as CREPT, which has been reported to promote cell cycle transition, promote tumorigenesis, and is a highly promising target for cancer therapy. Moreover, CREPT is only highly expressed in tumor cells, but not or lowly expressed in normal cells, so knockdown of CREPT can greatly inhibit tumor cell growth but not affect normal cell status.

Based on this background, Alfa Cytology identified a class of genes similar to CREPT as targets for anti-brain tumor drugs. We screen and synthesize small molecule inhibitors that specifically target binding, thus assisting our customers in developing drugs related to brain tumor inhibition and other research. We believe that this will be a novel anti-brain tumor small molecule drug with a new target, a new molecule, and a new mechanism of action.

We provide R & D services for the following small molecular inhibitors

• CA-170

CA-170 is a dual-target inhibitor of immune checkpoint programmed death ligand-1 (PD-L1) and V-domain immunoglobulin suppressor of T-cell activation (VISTA).

• Arginase inhibitors

It can trigger substrate conversion through inducible nitric oxide synthase (iNOS), which stimulates the production of reactive oxygen and nitrogen species and promotes immunosuppression.

• IDO1 (indoleamine 2, 3-dioxygenase 1) inhibitor

IDO1-mediated Trp catabolism promotes the differentiation of regulatory T cells (Tregs). By activating IDO1, tumor cells can effectively evade host immune surveillance. Therefore, the application of small molecule IDO1 inhibitors is an effective treatment for brain tumor patients to reconstitute immunogenic responses.

• CBP/EP300 bromodomain inhibitor

It not only impairs Treg cell function in the tumor microenvironment but also enhances the killing effect of NK cells and CD8⁺ T cells on tumor cells by upregulating the expression of NKG2D ligand on the surface of tumor cells.

If you are interested in our development services or have a unique molecule that needs to be developed, please feel free to contact us for the latest news. We look forward to a win-win collaboration with you on brain tumor-associated small molecule inhibitors.